4539.T Живые сигналы | Максимизируйте прибыль с Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 апр. 2024 @ 09:15):

Nippon Chemiphar Co., Ltd., together with its subsidiaries, manufactures, markets, imports, exports, and sells, ethical pharmaceuticals and diagnostic agents in Japan and internationally...

Stats
Объем за сегодня	18 700.00
Средний объем	5 074.00
Рыночная капитализация	5.74B
EPS	¥0 ( 2024-01-30 )
Дата следующего отчета о доходах	( ¥0 ) 2024-05-09
Last Dividend	¥50.00 ( 2023-03-30 )
Next Dividend	¥0 ( N/A )
P/E	-23.87
ATR14	¥4.47 (0.28%)

Nippon Chemiphar Co., Корреляция

10 Самые положительные корреляции

10 Самые отрицательные корреляции

Вы знали?

Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).

Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.

Nippon Chemiphar Co., Финансовые показатели

Annual	2022
Выручка:	¥31.56B
Валовая прибыль:	¥8.19B (25.94 %)
EPS:	¥93.92

FY	2022
Выручка:	¥31.56B
Валовая прибыль:	¥8.19B (25.94 %)
EPS:	¥93.92

FY	2022
Выручка:	¥32.51B
Валовая прибыль:	¥9.07B (27.91 %)
EPS:	¥194.33

FY	2021
Выручка:	¥31.54B
Валовая прибыль:	¥11.44B (36.28 %)
EPS:	¥137.75

Financial Reports:

No articles found.

Nippon Chemiphar Co., Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
¥0 (N/A)	¥0 (N/A)	¥50.00 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)

Nippon Chemiphar Co., Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 5.79 - average (59.94%) | Divividend Growth Potential Score: 1.787 - No dividend expected

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	¥30.00	2008-03-26
Last Dividend	¥50.00	2023-03-30
Next Dividend	¥0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	16	--
Total Paid Out	¥1 040.00	--
Avg. Dividend % Per Year	0.00%	--
Score	1.8	--
Div. Sustainability Score	5.79
Div.Growth Potential Score	1.787
Div. Directional Score	3.79	--

Next Divdend (Est)
(2025-03-19)

¥0 Estimate 0.00 %

Dividend Stability

0.05 Very Bad

Dividend Score

1.80

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for JPX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
7315.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
6564.T	Ex Dividend Junior	2024-03-28	Annually	0.00%
5915.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
4578.T	Ex Dividend Knight	2023-12-28	Semi-Annually	0.00%
3834.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
3085.T	Ex Dividend Knight	2023-06-29	Semi-Annually	0.00%
1951.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
9507.T	Ex Dividend Junior	2023-09-28	Annually	0.00%
8395.T	Ex Dividend Junior	2023-09-28	Semi-Annually	0.00%
7818.T	Ex Dividend Knight	2023-08-30	Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-0.00787	1.500	-0.157	-0.236	[0 - 0.5]
returnOnAssetsTTM	-0.00473	1.200	-0.158	-0.189	[0 - 0.3]
returnOnEquityTTM	-0.0130	1.500	-1.255	-1.883	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	2.43	0.800	2.86	2.29	[1 - 3]
quickRatioTTM	1.563	0.800	5.51	4.41	[0.8 - 2.5]
cashRatioTTM	0.747	1.500	6.96	10.00	[0.2 - 2]
debtRatioTTM	0.344	-1.500	4.27	-6.41	[0 - 0.6]
interestCoverageTTM	-3.58	1.000	-2.44	-2.44	[3 - 30]
operatingCashFlowPerShareTTM	796.41	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	796.41	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.934	-1.500	6.26	-9.40	[0 - 2.5]
grossProfitMarginTTM	0.251	1.000	9.15	9.15	[0.2 - 0.8]
operatingProfitMarginTTM	-0.0153	1.000	-2.31	-2.31	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.164	1.000	-0.199	-0.199	[0.2 - 2]
assetTurnoverTTM	0.601	0.800	9.33	7.46	[0.5 - 2]
Total Score				5.79

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-23.81	1.000	-2.51	0	[1 - 100]
returnOnEquityTTM	-0.0130	2.50	-0.807	-1.883	[0.1 - 1.5]
freeCashFlowPerShareTTM	796.41	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	3.14	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	796.41	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-0.246	1.500	-4.97	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0939	1.000	-0.153	0	[0.1 - 0.5]
Total Score				1.787

Nippon Chemiphar Co.,

Nippon Chemiphar Co., Ltd., together with its subsidiaries, manufactures, markets, imports, exports, and sells, ethical pharmaceuticals and diagnostic agents in Japan and internationally. It offers diagnostic products, such as IgE NC, a diagnostic kit that provides results and reveals total IgE levels, as well as 57 individual allergen reagents; and DP3000, a device for allergen-specific IgE measurements. The company also develops NC-2400, a PPAR-delta agonist; NC-2500, a novel advanced xanthine oxidoreductase inhibitor for the treatment of hyperuricemia/gout; and NC-2600, a P2X4 receptor antagonist for the treatment of neuropathic pain. In addition, it develops NC-2700, a novel urate transporter 1 inhibitor that enhance excretion urate to urine; NC-2800, a delta opioid receptor agonist for the treatment of depression/anxiety; Uralyt-U, an alkalization therapeutic drug; Soleton, an analgesic and anti-inflammatory drug; and Calvan, a hypertension therapeutic drug. Further, the company provides quasi-drugs, nutrients, health foods, cosmetics, and various type of creams. It distributes its generic pharmaceuticals through wholesalers to hospitals and pharmacies. The company was formerly known as Hitachi Chemical Co., Ltd. and changed its name to Nippon Chemiphar Co., Ltd. in 1970. Nippon Chemiphar Co., Ltd. was founded in 1950 and is headquartered in Tokyo, Japan.